Identification

Name
Nimesulide
Accession Number
DB04743
Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Description

Nimesulide is a relatively COX-2 selective, non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties. Its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old. Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.

Structure
Thumb
Synonyms
Not Available
External IDs
R 805 / R-805
International/Other Brands
Ainex / Aulin / Coxtal / Eskaflam / Mesulid / Nilsid / Nimalox / Nimside / Nise / Octaprin / Sintalgin / Sulide
Categories
UNII
V4TKW1454M
CAS number
51803-78-2
Weight
Average: 308.31
Monoisotopic: 308.046692194
Chemical Formula
C13H12N2O5S
InChI Key
HYWYRSMBCFDLJT-UHFFFAOYSA-N
InChI
InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3
IUPAC Name
N-(4-nitro-2-phenoxyphenyl)methanesulfonamide
SMILES
CS(=O)(=O)NC1=C(OC2=CC=CC=C2)C=C(C=C1)[N+]([O-])=O

Pharmacology

Indication

For the treatment of acute pain, the symptomatic treatment of osteoarthritis and primary dysmenorrhoea in adolescents and adults above 12 years old.

Structured Indications
Not Available
Pharmacodynamics

Food, gender and advanced age have negligible effects on nimesulide pharmacokinetics.

Mechanism of action

The therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine.

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
UGroup IIE secretory phospholipase A2Not AvailableHuman
ULactotransferrinNot AvailableHuman
Absorption

Rapidly absorbed following oral administration.

Volume of distribution
Not Available
Protein binding

>97.5%

Metabolism

Hepatic. Extensive biotransformation, mainly to 4-hydroxynimesulide (which also appears to be biologically active).

Route of elimination

Renal (50%), fecal (29%)

Half life

1.8–4.7 hours

Clearance
Not Available
Toxicity

Oral TDLO (human): 1.429 mg/kg; Oral TDLO (woman): 2 mg/kg; Oral LD50 (rat): 200 mg/kg; Oral LD50 (mouse): 392 mg/kg

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Nimesulide is combined with 19-norandrostenedione.Experimental, Illicit
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Nimesulide.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Nimesulide.Vet Approved
5-androstenedioneThe risk or severity of adverse effects can be increased when Nimesulide is combined with 5-androstenedione.Experimental, Illicit
AbciximabNimesulide may increase the anticoagulant activities of Abciximab.Approved
AcebutololNimesulide may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolNimesulide may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinNimesulide may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Nimesulide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aldosterone.Experimental, Investigational
AldoxorubicinNimesulide may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Nimesulide.Approved, Investigational
AliskirenNimesulide may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aloxiprin.Experimental
AlprenololNimesulide may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Nimesulide.Approved, Investigational
AlteplaseNimesulide may increase the anticoagulant activities of Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Amcinonide.Approved
AmikacinNimesulide may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideNimesulide may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Aminosalicylic Acid.Approved
AmobarbitalThe metabolism of Nimesulide can be increased when combined with Amobarbital.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Nimesulide.Approved, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nimesulide.Approved, Investigational
AmrubicinNimesulide may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideNimesulide may increase the anticoagulant activities of Anagrelide.Approved
AncrodNimesulide may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Nimesulide is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Nimesulide is combined with anecortave acetate.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Nimesulide.Approved, Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Anisodamine.Investigational
AnistreplaseNimesulide may increase the anticoagulant activities of Anistreplase.Approved
AnnamycinNimesulide may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Nimesulide.Approved
Antithrombin III humanNimesulide may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apocynin.Investigational
ApramycinNimesulide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Nimesulide is combined with Apremilast.Approved, Investigational
ArbekacinNimesulide may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinNimesulide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanNimesulide may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Nimesulide.Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Nimesulide.Approved
AstaxanthinNimesulide may increase the anticoagulant activities of Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Atamestane.Investigational
AtenololNimesulide may decrease the antihypertensive activities of Atenolol.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Atorvastatin.Approved
AtosibanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Atosiban.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Nimesulide.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nimesulide.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Nimesulide.Experimental
BalsalazideNimesulide may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarbexacloneThe metabolism of Nimesulide can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Nimesulide can be increased when combined with Barbital.Illicit
BatroxobinNimesulide may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminNimesulide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololNimesulide may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinNimesulide may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinNimesulide may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nimesulide.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Nimesulide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benoxaprofen.Withdrawn
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Nimesulide.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Nimesulide.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Betamethasone.Approved, Vet Approved
BetaxololNimesulide may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Nimesulide.Approved, Investigational
BevantololNimesulide may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bevonium.Experimental
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Nimesulide.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Nimesulide.Approved, Investigational
BisoprololNimesulide may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinNimesulide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololNimesulide may decrease the antihypertensive activities of Bopindolol.Approved
Brefeldin AThe risk or severity of adverse effects can be increased when Brefeldin A is combined with Nimesulide.Experimental
BrinaseNimesulide may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Nimesulide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bucillamine.Investigational
BucindololBucindolol may increase the hypotensive activities of Nimesulide.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bufexamac.Experimental
BuflomedilNimesulide may increase the antiplatelet activities of Buflomedil.Experimental
BufuralolNimesulide may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Bumadizone.Experimental
BumetanideNimesulide may decrease the diuretic activities of Bumetanide.Approved
BunazosinBunazosin may increase the hypotensive activities of Nimesulide.Investigational
BupranololNimesulide may decrease the antihypertensive activities of Bupranolol.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Nimesulide.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Nimesulide.Approved
ButylphthalideNimesulide may increase the antiplatelet activities of Butylphthalide.Investigational
Calcium AcetateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Phosphate.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nimesulide.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Nimesulide.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Nimesulide.Withdrawn
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Nimesulide.Experimental
CangrelorNimesulide may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabNimesulide may increase the anticoagulant activities of Caplacizumab.Investigational
Capric acidThe risk or severity of adverse effects can be increased when Capric acid is combined with Nimesulide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nimesulide.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Nimesulide is combined with Carbaspirin calcium.Experimental, Investigational
CarbomycinThe metabolism of Nimesulide can be decreased when combined with Carbomycin.Vet Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Nimesulide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Nimesulide.Approved, Vet Approved, Withdrawn
CarteololNimesulide may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Nimesulide.Approved, Investigational
CaseinThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Casein.Approved
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Nimesulide.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Nimesulide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nimesulide.Approved, Investigational
CeliprololNimesulide may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CerivastatinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Cerivastatin.Withdrawn
CertoparinNimesulide may increase the anticoagulant activities of Certoparin.Approved, Investigational
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Nimesulide.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Nimesulide.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Nimesulide.Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Nimesulide.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nimesulide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ciclesonide.Approved, Investigational
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Nimesulide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nimesulide.Approved
CilostazolNimesulide may increase the anticoagulant activities of Cilostazol.Approved
CimetidineThe serum concentration of Nimesulide can be increased when it is combined with Cimetidine.Approved
CinoxacinNimesulide may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidNimesulide may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Nimesulide can be decreased when combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nimesulide.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Nimesulide.Vet Approved
CloranololNimesulide may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenNimesulide may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneNimesulide may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Nimesulide.Approved, Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Nimesulide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Nimesulide is combined with Collagenase clostridium histolyticum.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nimesulide.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Nimesulide is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Nimesulide.Experimental
CyclosporineNimesulide may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateNimesulide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinNimesulide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidNimesulide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Nimesulide.Investigational
DarexabanNimesulide may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Nimesulide.Approved, Investigational
DaunorubicinNimesulide may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deferasirox.Approved, Investigational
DefibrotideNimesulide may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Nimesulide.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dersalazine.Investigational
DesirudinNimesulide may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desmopressin.Approved
DesmoteplaseNimesulide may increase the anticoagulant activities of Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Nimesulide.Approved, Investigational
DextranNimesulide may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Nimesulide may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Nimesulide may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Nimesulide may increase the anticoagulant activities of Dextran 75.Approved
DibekacinNimesulide may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DichloropheneThe risk or severity of adverse effects can be increased when Dichlorophene is combined with Nimesulide.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Nimesulide.Approved, Vet Approved
DicoumarolNimesulide may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Nimesulide is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nimesulide.Approved
DihydrostreptomycinNimesulide may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Nimesulide.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Nimesulide.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Nimesulide.Approved
DiphenadioneNimesulide may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleNimesulide may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleNimesulide may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DoxazosinDoxazosin may increase the hypotensive activities of Nimesulide.Approved
DoxorubicinNimesulide may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneNimesulide may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaNimesulide may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Nimesulide is combined with E-6201.Investigational
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Nimesulide.Approved
Edetic AcidNimesulide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanNimesulide may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Nimesulide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Nimesulide.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nimesulide.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nimesulide.Approved
EnoxacinNimesulide may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinNimesulide may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Nimesulide.Experimental
EpanololNimesulide may decrease the antihypertensive activities of Epanolol.Experimental
EpinastineEpinastine may increase the antiplatelet activities of Nimesulide.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Nimesulide is combined with Epirizole.Approved
EpirubicinNimesulide may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneNimesulide may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinNimesulide may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineNimesulide may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nimesulide.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nimesulide.Approved
EptifibatideNimesulide may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Nimesulide is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Equilin.Approved
ErythromycinThe metabolism of Nimesulide can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololNimesulide may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Estrone sulfate.Approved
Etacrynic acidNimesulide may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Nimesulide.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ethenzamide.Experimental
Ethyl biscoumacetateNimesulide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Nimesulide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Nimesulide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Nimesulide is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Nimesulide is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Nimesulide.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Nimesulide.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fentiazac.Experimental
FenticonazoleThe risk or severity of adverse effects can be increased when Fenticonazole is combined with Nimesulide.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Feprazone.Experimental
Ferulic acidNimesulide may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinNimesulide may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nimesulide.Approved, Investigational
FleroxacinNimesulide may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Nimesulide.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluasterone.Investigational
FluconazoleThe serum concentration of Nimesulide can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Nimesulide.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fludrocortisone.Approved
FluindioneNimesulide may increase the anticoagulant activities of Fluindione.Investigational
FlumequineNimesulide may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Nimesulide.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nimesulide.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluticasone propionate.Approved
FlutrimazoleThe risk or severity of adverse effects can be increased when Flutrimazole is combined with Nimesulide.Experimental
FluvastatinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Fluvastatin.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Nimesulide.Approved, Nutraceutical, Vet Approved
FondaparinuxNimesulide may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumNimesulide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Nimesulide.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nimesulide.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Nimesulide.Approved
FramycetinNimesulide may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideNimesulide may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateNimesulide may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinNimesulide may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinNimesulide may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Nimesulide.Approved, Withdrawn
GemifloxacinNimesulide may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinNimesulide may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinNimesulide may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ANimesulide may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GlucosamineGlucosamine may increase the antiplatelet activities of Nimesulide.Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Nimesulide.Experimental
GPX-150Nimesulide may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinNimesulide may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Nimesulide.Approved, Vet Approved
GuacetisalThe risk or severity of adverse effects can be increased when Nimesulide is combined with Guacetisal.Experimental
HachimycinThe risk or severity of adverse effects can be increased when Hachimycin is combined with Nimesulide.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Nimesulide.Approved, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Nimesulide is combined with HE3286.Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Nimesulide is combined with Hemoglobin crosfumaril.Experimental
HeparinNimesulide may increase the anticoagulant activities of Heparin.Approved, Investigational
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Nimesulide.Approved, Investigational
HexobarbitalThe metabolism of Nimesulide can be increased when combined with Hexobarbital.Approved
HigenamineNimesulide may increase the anticoagulant activities of Higenamine.Investigational
HydralazineNimesulide may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nimesulide.Approved, Investigational
HydroxytyrosolNimesulide may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Hygromycin BNimesulide may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Nimesulide.Approved
IbudilastNimesulide may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Nimesulide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Nimesulide is combined with Icatibant.Approved
Icosapent ethylNimesulide may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdarubicinNimesulide may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxNimesulide may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilNimesulide may increase the antiplatelet activities of Ifenprodil.Approved, Investigational, Withdrawn
IfetrobanNimesulide may increase the antiplatelet activities of Ifetroban.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nimesulide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nimesulide.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Nimesulide.Approved
IndenololNimesulide may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenNimesulide may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Nimesulide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Indoprofen.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Nimesulide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nimesulide.Approved, Investigational
IsepamicinNimesulide may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Nimesulide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Nimesulide is combined with Istaroxime.Investigational
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Nimesulide.Approved, Investigational
JosamycinThe metabolism of Nimesulide can be decreased when combined with Josamycin.Approved, Investigational
KanamycinNimesulide may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Kebuzone.Experimental
KetanserinNimesulide may increase the antiplatelet activities of Ketanserin.Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Nimesulide.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Nimesulide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nimesulide.Approved
KitasamycinThe metabolism of Nimesulide can be decreased when combined with Kitasamycin.Experimental
LabetalolLabetalol may increase the hypotensive activities of Nimesulide.Approved
LandiololNimesulide may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Nimesulide.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Nimesulide.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Nimesulide.Approved, Investigational
LepirudinNimesulide may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanNimesulide may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololNimesulide may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinNimesulide may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostLimaprost may increase the antiplatelet activities of Nimesulide.Approved, Investigational
LinsidomineNimesulide may increase the antiplatelet activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nimesulide.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Nimesulide.Approved
LonazolacThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nimesulide.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Loteprednol.Approved
LovastatinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nimesulide.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Nimesulide.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Nimesulide.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nimesulide.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Nimesulide.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Nimesulide is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nimesulide.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nimesulide.Approved
MelagatranNimesulide may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Nimesulide.Approved, Vet Approved
MepartricinThe risk or severity of adverse effects can be increased when Mepartricin is combined with Nimesulide.Experimental
MepindololNimesulide may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Nimesulide is combined with Metamizole.Investigational, Withdrawn
MethohexitalThe metabolism of Nimesulide can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nimesulide.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Nimesulide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Methyl salicylate.Approved, Vet Approved
MethylphenobarbitalThe metabolism of Nimesulide can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Methylprednisolone.Approved, Vet Approved
MetipranololNimesulide may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Nimesulide.Approved
MetoprololNimesulide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideNimesulide may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Nimesulide.Experimental
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Nimesulide.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Nimesulide.Approved, Investigational, Vet Approved
MicronomicinNimesulide may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MilrinoneMilrinone may increase the antiplatelet activities of Nimesulide.Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Nimesulide.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Nimesulide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nimesulide.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Mometasone.Approved, Vet Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Nimesulide.Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Nimesulide.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nimesulide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nimesulide.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Nimesulide.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Nimesulide.Approved
NadololNimesulide may decrease the antihypertensive activities of Nadolol.Approved
NadroparinNimesulide may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNimesulide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe metabolism of Nimesulide can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Nimesulide.Approved
NaftopidilNimesulide may increase the antiplatelet activities of Naftopidil.Investigational
Nalidixic AcidNimesulide may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Nimesulide.Approved, Vet Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Nimesulide.Approved
NCX 1022The risk or severity of adverse effects can be increased when Nimesulide is combined with NCX 1022.Investigational
NeamineNimesulide may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololNimesulide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinNimesulide may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinNimesulide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Nimesulide.Approved
NetilmicinNimesulide may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Nimesulide.Approved
NifuratelThe risk or severity of adverse effects can be increased when Nifuratel is combined with Nimesulide.Experimental
Nikkomycin ZThe risk or severity of adverse effects can be increased when Nikkomycin Z is combined with Nimesulide.Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Nitroaspirin.Investigational
NitroprussideNimesulide may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Nimesulide.Approved
NorfloxacinNimesulide may increase the neuroexcitatory activities of Norfloxacin.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Nimesulide.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nimesulide is combined with Obinutuzumab.Approved
OleandomycinThe metabolism of Nimesulide can be decreased when combined with Oleandomycin.Vet Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nimesulide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nimesulide.Approved
OlsalazineNimesulide may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Nimesulide is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Nimesulide.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Nimesulide.Approved, Nutraceutical
OmoconazoleThe risk or severity of adverse effects can be increased when Omoconazole is combined with Nimesulide.Experimental
OrgoteinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Orgotein.Vet Approved
OtamixabanNimesulide may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Nimesulide.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Nimesulide.Approved
Oxolinic acidNimesulide may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololNimesulide may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nimesulide.Approved, Withdrawn
OzagrelNimesulide may increase the anticoagulant activities of Ozagrel.Investigational
PafuramidineThe risk or severity of adverse effects can be increased when Pafuramidine is combined with Nimesulide.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Nimesulide is combined with Parecoxib.Approved
ParnaparinNimesulide may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParomomycinNimesulide may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Parthenolide.Investigational
PazufloxacinNimesulide may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinNimesulide may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololNimesulide may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateNimesulide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Nimesulide.Approved
PentobarbitalThe metabolism of Nimesulide can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nimesulide.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Nimesulide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nimesulide.Approved
PhenindioneNimesulide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Nimesulide can be increased when combined with Phenobarbital.Approved
PhenprocoumonNimesulide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nimesulide.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Nimesulide.Approved, Vet Approved
PicotamideNimesulide may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Nimesulide.Approved, Investigational
PindololNimesulide may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidNimesulide may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinNimesulide may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideNimesulide may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pirfenidone.Approved, Investigational
Piromidic acidNimesulide may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Nimesulide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pirprofen.Experimental
PitavastatinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pitavastatin.Approved
Platelet Activating FactorNimesulide may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinNimesulide may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinNimesulide may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Nimesulide.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Nimesulide.Approved, Investigational, Vet Approved
PractololNimesulide may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Nimesulide.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prasterone sulfate.Investigational
PrasugrelNimesulide may increase the anticoagulant activities of Prasugrel.Approved
PravastatinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pravastatin.Approved
PrazosinPrazosin may increase the hypotensive activities of Nimesulide.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Nimesulide can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Nimesulide can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Propacetamol.Approved, Investigational
PropranololNimesulide may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Nimesulide.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Nimesulide.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Nimesulide.Vet Approved
Protein CNimesulide may increase the anticoagulant activities of Protein C.Approved
Protein S humanNimesulide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeNimesulide may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinNimesulide may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Nimesulide is combined with PTC299.Investigational
PuromycinNimesulide may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrrolnitrinThe risk or severity of adverse effects can be increased when Pyrrolnitrin is combined with Nimesulide.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nimesulide.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Nimesulide.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Nimesulide.Experimental
RamatrobanNimesulide may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nimesulide.Approved
RelcovaptanNimesulide may increase the antiplatelet activities of Relcovaptan.Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Nimesulide.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Nimesulide.Approved, Experimental, Investigational
ReteplaseNimesulide may increase the anticoagulant activities of Reteplase.Approved
ReviparinNimesulide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinNimesulide may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Nimesulide.Approved
RifabutinThe serum concentration of Nimesulide can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Nimesulide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nimesulide can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Nimesulide can be decreased when it is combined with Rifaximin.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Risedronate.Approved, Investigational
RivaroxabanNimesulide may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Nimesulide.Investigational, Withdrawn
RosiglitazoneNimesulide may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RosoxacinNimesulide may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RosuvastatinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Rosuvastatin.Approved
RufloxacinNimesulide may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinNimesulide may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nimesulide.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Salicylamide.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Nimesulide.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Nimesulide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Nimesulide.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Nimesulide.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Nimesulide.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Nimesulide.Approved
SarpogrelateNimesulide may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseNimesulide may increase the anticoagulant activities of Saruplase.Experimental
SecobarbitalThe metabolism of Nimesulide can be increased when combined with Secobarbital.Approved, Vet Approved
SelexipagNimesulide may increase the anticoagulant activities of Selexipag.Approved
SemapimodThe risk or severity of adverse effects can be increased when Nimesulide is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Nimesulide is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Nimesulide is combined with Serrapeptase.Investigational
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Nimesulide.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Nimesulide.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Nimesulide.Approved
SimvastatinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Simvastatin.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Nimesulide.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Nimesulide.Approved, Investigational
SisomicinNimesulide may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinNimesulide may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Nimesulide.Approved
SolithromycinThe metabolism of Nimesulide can be decreased when combined with Solithromycin.Investigational
SotalolNimesulide may decrease the antihypertensive activities of Sotalol.Approved
SP1049CNimesulide may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinNimesulide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinNimesulide may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Nimesulide.Approved
SRT501The risk or severity of adverse effects can be increased when Nimesulide is combined with SRT501.Investigational
StreptokinaseNimesulide may increase the anticoagulant activities of Streptokinase.Approved, Investigational
StreptomycinNimesulide may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinNimesulide may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Nimesulide.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Nimesulide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Nimesulide.Approved
SulodexideNimesulide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Nimesulide.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Nimesulide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Suxibuzone.Experimental
TacrolimusNimesulide may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Nimesulide.Approved
TalinololNimesulide may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Nimesulide.Approved
TamsulosinTamsulosin may increase the hypotensive activities of Nimesulide.Approved, Investigational
TarenflurbilThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Nimesulide.Approved
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Nimesulide.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Technetium Tc-99m medronate.Approved
TelithromycinThe metabolism of Nimesulide can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nimesulide.Approved, Investigational
TemafloxacinNimesulide may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Nimesulide.Experimental, Investigational
TenecteplaseNimesulide may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Nimesulide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tepoxalin.Vet Approved
TerazosinTerazosin may increase the hypotensive activities of Nimesulide.Approved
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Nimesulide.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Nimesulide.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Teriflunomide.Approved
TertatololNimesulide may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneNimesulide may increase the antiplatelet activities of Tesmilifene.Investigational
ThiamylalThe metabolism of Nimesulide can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Nimesulide can be increased when combined with Thiopental.Approved, Vet Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Nimesulide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nimesulide.Approved
TicagrelorNimesulide may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineNimesulide may increase the anticoagulant activities of Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololNimesulide may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tinoridine.Investigational
TinzaparinNimesulide may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolNimesulide may increase the anticoagulant activities of Tioclomarol.Experimental
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Nimesulide.Approved
TipranavirTipranavir may increase the antiplatelet activities of Nimesulide.Approved, Investigational
TirofibanNimesulide may increase the anticoagulant activities of Tirofiban.Approved
TixocortolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tixocortol.Approved, Withdrawn
TobramycinNimesulide may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolciclateThe risk or severity of adverse effects can be increased when Tolciclate is combined with Nimesulide.Experimental
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Nimesulide.Approved
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Nimesulide.Approved, Vet Approved
TorasemideNimesulide may decrease the diuretic activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tositumomab.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nimesulide.Approved
TranilastThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tranilast.Approved, Investigational
TrapidilNimesulide may increase the antiplatelet activities of Trapidil.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Nimesulide.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Nimesulide.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Triamcinolone.Approved, Vet Approved
TriamtereneNimesulide may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Nimesulide.Approved, Vet Approved
TriflusalNimesulide may increase the anticoagulant activities of Triflusal.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Nimesulide.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Nimesulide.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Nimesulide is combined with Trolamine salicylate.Approved
TrovafloxacinNimesulide may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinNimesulide may increase the anticoagulant activities of Troxerutin.Investigational
TylosinThe metabolism of Nimesulide can be decreased when combined with Tylosin.Vet Approved
UbidecarenoneThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ubidecarenone.Approved, Investigational, Nutraceutical
UlobetasolThe risk or severity of adverse effects can be increased when Nimesulide is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Nimesulide.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Nimesulide.Investigational
UrokinaseNimesulide may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Nimesulide.Investigational, Withdrawn
ValrubicinNimesulide may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nimesulide.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Nimesulide.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Nimesulide.Approved, Nutraceutical, Vet Approved
VorapaxarNimesulide may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Nimesulide.Approved, Investigational
WarfarinNimesulide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranNimesulide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Nimesulide.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Nimesulide.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Nimesulide is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinNimesulide may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinNimesulide may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Bernard Pirotte, Geraldine Piel, Philippe Neven, Isabelle Delneuville, Joszef Geczy, "Water-soluble nimesulide salt and its preparation, aqueous dolution containing it, nimesulide-based combinations and their uses." U.S. Patent US5756546, issued November, 1991.

US5756546
General References
Not Available
External Links
KEGG Drug
D01049
PubChem Compound
4495
PubChem Substance
46507721
ChemSpider
4339
BindingDB
50056999
ChEBI
44445
ChEMBL
CHEMBL56367
Therapeutic Targets Database
DPR000079
PharmGKB
PA137179528
HET
NIM
Drugs.com
Drugs.com Drug Page
Wikipedia
Nimesulide
ATC Codes
M02AA26 — NimesulideM01AX17 — Nimesulide
PDB Entries
1zwp / 2oth / 3e9x / 3n8x / 3ql6 / 4eix
MSDS
Download (23.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailablePain1
2CompletedPreventionCancer, Breast1
3RecruitingTreatmentAcute and Chronic Inflammation / Indigestion1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)1
4CompletedTreatmentPharyngitis1
4WithdrawnTreatmentUpper Respiratory Tract Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)143-144.5 °CPhysProp
logP2.60SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility0.0182 mg/mLALOGPS
logP2.56ALOGPS
logP1.79ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)6.86ChemAxon
pKa (Strongest Basic)-8.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area101.22 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity76.31 m3·mol-1ChemAxon
Polarizability28.87 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9952
Blood Brain Barrier+0.6341
Caco-2 permeable-0.55
P-glycoprotein substrateNon-substrate0.8267
P-glycoprotein inhibitor INon-inhibitor0.5634
P-glycoprotein inhibitor IINon-inhibitor0.8129
Renal organic cation transporterNon-inhibitor0.8943
CYP450 2C9 substrateNon-substrate0.6235
CYP450 2D6 substrateNon-substrate0.8055
CYP450 3A4 substrateSubstrate0.5257
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.7628
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8952
Ames testAMES toxic0.6488
CarcinogenicityNon-carcinogens0.6116
BiodegradationNot ready biodegradable0.9901
Rat acute toxicity3.0832 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5345
hERG inhibition (predictor II)Non-inhibitor0.5574
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000x-0291000000-646d9ba99afae997e8ed
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000x-0291000000-d80621f80ce111da876f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0910000000-a5c76988cf3380fc5b30
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0900000000-d75eef7fee376750fef9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0900000000-3e21c4ed858c88f9fc59
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0459000000-055f5763b37c21230aaa
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0ue9-2920000000-2d4d6a28e043baa5549a

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Diphenylethers
Alternative Parents
Diarylethers / Sulfanilides / Nitrobenzenes / Nitroaromatic compounds / Phenoxy compounds / Phenol ethers / Organic sulfonamides / Organosulfonamides / Aminosulfonyl compounds / Organic oxoazanium compounds
show 6 more
Substituents
Diphenylether / Diaryl ether / Sulfanilide / Nitrobenzene / Phenoxy compound / Nitroaromatic compound / Phenol ether / Organic sulfonic acid amide / Organosulfonic acid amide / Organic sulfonic acid or derivatives
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
C-nitro compound, aromatic ether, sulfonamide (CHEBI:44445)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Rainsford KD: Nimesulide -- a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin. 2006 Jun;22(6):1161-70. [PubMed:16846549]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phospholipase a2 activity
Specific Function
PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.
Gene Name
PLA2G2E
Uniprot ID
Q9NZK7
Uniprot Name
Group IIE secretory phospholipase A2
Molecular Weight
15988.525 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate.Lactotransferrin is a major iron-binding and multifu...
Gene Name
LTF
Uniprot ID
P02788
Uniprot Name
Lactotransferrin
Molecular Weight
78181.225 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 11, 2007 11:49 / Updated on December 01, 2017 15:32